Fourth Annual Community Oncology Conference

Volume 3, Number 6, Supplement 2 (June 2006)

Emerging Strategies for the Treatment of Metastatic Colorectal Cancer

This supplement is a continuing medical education activity jointly sponsored by Vanderbilt University School of Medicine and the Continuing Education Alliance. To receive CME credit, you must complete the CME evaluation form and quiz online at www.nprcrc.org no later than June 15, 2007 and correctly answer 80% of the questions.

Information About This CME Activity
Target Audience • Faculty Affiliations • Learning Objectives • Faculty Disclosures • Americans With Disabilities Act • How to Receive Credit • Disclaimer • About National Peer Reviews in Colorectal Cancer

full text 112 kb
Release date: June 15, 2006 • Expiration date: June 15, 2007

Contents

5

  

Metastatic colorectal cancer: treatment strategies with current cytotoxic regimens

Charles D. Blanke, MD

Oregon Health & Science University, Portland, OR

abstract full text 204 kb

12

  

Integrating targeted agents into planning strategies for the treatment of metastatic colorectal cancer

David H. Ilson, MD, PhD

Weill-Cornell Medical College and Memorial Sloan-Kettering Cancer Center, New York, NY

abstract full text 107 kb

18

  

Strategic planning for patients who present with metastatic colorectal cancer

Al B. Benson III, MD

Northwestern University Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center, Chicago, IL

abstract full text 218 kb

26

  

Current approaches for liver-only metastases in colorectal cancer

Nancy E. Kemeny, MD

Weill-Cornell Medical College and Memorial Sloan-Kettering Cancer Center, New York, NY

abstract full text 191 kb

36

  

Clinician challenges in the community setting: treatment selection for metastatic colorectal cancer

Lee S. Schwartzberg, MD

University of Tennessee College of Medicine and The West Clinic, Memphis, TN

full text 88 kb

41

  

Self-assessment questions

full text 49 kb

Supported by an unrestricted educational grant from Pfizer Inc

© 2006 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

The opinions expressed herein are those of the authors or advertisers. The authors, editors, and publishers make every effort to ensure that no inaccurate or misleading data, opinion, or statement is published in this journal and that drug names, dosages, and recommendations are accurate. However, readers should confirm all dosage schedules against the manufacturer’s package information data. The Publisher, Editorial Board, and their employees accept no liability whatsoever for the consequences of any inaccurate or misleading data, opinion, or statement.